Recent research conducted by scientists in Ireland has revealed the significant role of lipid-rich fluid in the abdomen, ...

Lipid receptor SR-B1 identified as a potential immunotherapy target to boost NK cell antitumor response in advanced ovarian ...

New research led by Irish scientists has uncovered how lipid-rich fluid in the abdomen, known as ascites, plays a central ...

Alcohol consumption poses a significant global health risk, contributing to numerous diseases and injuries, especially among ...

Hepatocellular carcinoma (HCC) accounts for more than 90% of instances of liver cancer, which ranks as the fifth most frequent cancer in the United States. Furthermore, Texas leads the nation in the ...

The FDA has granted full approval to Bristol Myers Squibb’s (BMS) dual immunotherapy regimen of Opdivo (nivolumab) plus Yervoy (ipilimumab) for adults with unresectable or metastatic hepatocellular ...

The trial compared the combo against the investigator’s choice of tyrosine kinase inhibitor monotherapy in the unresectable or advanced hepatocellular carcinoma patient group. Credit: ...

The FDA approved the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC). This regulatory decision is ...

The patient has a history of atrial fibrillation that is being managed with apixaban and renal cell carcinoma ... ascites. A patient presenting with fever, abdominal tenderness, and jaundice ...

The study updated the current understanding of ICIs in hepatocellular carcinoma and identified vital future directions for research, such as the exploration of mechanisms of immune evasion, developing ...